JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Investor Presentation
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals filed its Q4 and FY25 investor presentation. FY25 revenue grew 12% to INR 3,918 crores, with domestic formulations up 20% to INR 2,269 crores and international business up 4% to INR 1,649 crores. Operating EBITDA crossed INR 1,000 crores for the first time, reaching INR 1,087 crores (16% growth) with margins improving 70 bps to 27.7%. Net profit grew 19% to INR 660 crores, and the company turned net cash positive at INR 689 crores (vs INR 107 crores last year). ROCE improved to 32%. The company now has 6 brands in the top 300 of the Indian pharma market, ranks #8 in cardiology, and is among the top 5 global CDMOs for lozenges.
Strong all-round performance with margin expansion, robust cash generation, and a net cash balance sheet should be viewed positively by investors. The company has provided clear forward guidance targeting 200-400 bps growth premium over IPM and sustained 27-29% EBITDA margins, signaling confidence in continued outperformance.